Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Will Unload Nutrition Division, Keep Consumer Product Unit

This article was originally published in The Tan Sheet

Executive Summary

Pfizer will divest or spin off its nutrition unit but the firm will keep its consumer product business and look into future OTC switches.
Advertisement

Related Content

Novartis Seems Close to Consumer Health Sale – Analyst
Novartis Seems Close to Consumer Health Sale – Analyst
Pfizer Reorganizes Internally, Closer To Decision On Splitting Business
Pfizer Reorganizes Internally, Closer To Decision On Splitting Business
Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio
Lipitor OTC Switch Would Force Pfizer To Clear Big Research Hurdles
Pfizer Consumer Chief Sees Chronic Conditions In OTC Future
Pfizer CEO Read Expects Gradual Plans For Change In Second Half 2011
Pfizer CEO Read Expects Gradual Plans For Change In Second Half 2011
Mead Johnson Set Loose To Navigate Market, Shifting Economic Winds 

Topics

Advertisement
UsernamePublicRestriction

Register

PS105171

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel